Quanta Presents Class-Leading Monotherapy Data for QTX3034 in KRAS G12D-Mutant Advanced Endometrial Cancer at the EORTC-NCI-AACR Symposium

On November 20, 2026 Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS-driven cancers, reported encouraging clinical data for its oral G12D-preferring multi-KRAS inhibitor QTX3034 in patients with KRAS G12D-mutant endometrial cancer. The late-breaking oral presentation at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium 2026 describes data demonstrating substantial and durable anti-tumor activity with QTX3034 monotherapy in a heavily pretreated patient population that had received a median of four prior lines of therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among 11 patients with KRAS G12D-mutant endometrial cancer treated with QTX3034, the objective response rate (ORR) was 55%, including five partial responses and one complete response. Responses occurred rapidly, with a median time to response of 1.3 months, and were durable, with a median duration of response of 9.7 months. Activity was particularly pronounced among patients with endometrioid histology, the most common subtype of endometrial cancer, where four of five patients, or 80%, achieved an objective response. QTX3034 monotherapy was generally well tolerated, with primarily low-grade adverse events, low rates of dose modification, and no treatment-related adverse events leading to discontinuation.

"These results provide encouraging evidence that direct KRAS inhibition can drive meaningful and durable tumor responses in patients with KRAS G12D-mutant endometrial cancer who have progressed following established therapies," said Judy S. Wang, M.D., Florida Cancer Specialists/Sarah Cannon Research Institute and presenting author of the study. "The depth and durability of the responses are notable in this heavily pretreated population and support further evaluation of QTX3034 in this molecularly defined subset of endometrial cancer."

All 11 patients had mismatch repair-proficient tumors and had previously received chemotherapy and immune checkpoint inhibitor therapy, a clinical setting in which additional treatment options are needed. Seventy-three percent had received at least two prior lines of therapy, 45% had previously received an antibody-drug conjugate, and 36% had received a MAPK-targeting agent.

"We believe these results establish a class-leading clinical signal for QTX3034 in KRAS G12D-mutant endometrial cancer," said Perry Nisen, M.D., Ph.D., Chief Executive Officer of Quanta. "We observed objective responses in more than half of all endometrial cancer patients treated and in four of five patients with endometrioid histology. Together with a tolerable safety profile and high dose intensity, these data strengthen the clinical evidence supporting QTX3034 and provide a clear rationale for further development in KRAS G12D-mutant endometrial cancer."

(Press release, Quanta Therapeutics, NOV 20, 2026, View Source [SID1234675049])